Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Acumen Pharmaceuticals (ABOS)
NASDAQ:ABOS
Holding ABOS?
Track your performance easily
ABOS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.81 - $5.76
Previous Close$2.22
Volume324.83K
Average Volume (3M)415.63K
Market Cap
$136.38M
Enterprise Value-$94.37M
Total Cash (Recent Filing)$260.47M
Total Debt (Recent Filing)$29.72M
Price to Earnings (P/E)―
Beta1.10
Next Earnings
Nov 11, 2024EPS Estimate
-$0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.11
Shares Outstanding60,079,778
10 Day Avg. Volume203,380
30 Day Avg. Volume415,632
Standard Deviation0.29
R-Squared0.00021
Alpha-0.00620
Financial Highlights & Ratios
Price to Book (P/B)0.56
Price to Sales (P/S)27276.22
Price to Cash Flow (P/CF)-2.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-18.87K
Enterprise Value/Gross Profit-18.87K
Enterprise Value/Ebitda2.27
Forecast
1Y Price Target
$11.00Price Target Upside395.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Acumen Pharmaceuticals News
PremiumCompany Announcements
Acumen Pharmaceuticals Unveils Updated Corporate Presentation and Financials
Bulls Say, Bears Say
Bulls Say
Drug EfficacyRobust reductions in biomarkers linked to disease pathology from phase 1 data add to the conviction that sabirnetug will benefit cognition.
Market PotentialThe Leqembi launch has been strong despite challenges, indicating a favorable launch environment for sabirnetug.
Safety ProfileData to date suggest that ACU193 is safer than lecanemab and much safer than donanemab.
Bears Say
Investor SentimentInvestor sentiment negatively affected by challenges faced by other anti-amyloid beta monoclonal antibody developers.
Market LaunchThe potential launch of ACU193 has been pushed back by about two years.
Safety IssuesThe approach provides benefits to patients at the expense of safety issues.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ABOS FAQ
What was Acumen Pharmaceuticals’s price range in the past 12 months?
Acumen Pharmaceuticals lowest stock price was $1.81 and its highest was $5.76 in the past 12 months.
What is Acumen Pharmaceuticals’s market cap?
Currently, no data Available
When is Acumen Pharmaceuticals’s upcoming earnings report date?
Acumen Pharmaceuticals’s upcoming earnings report date is Nov 11, 2024 which is in 65 days.
How were Acumen Pharmaceuticals’s earnings last quarter?
Acumen Pharmaceuticals released its earnings results on Aug 13, 2024. The company reported -$0.34 earnings per share for the quarter, missing the consensus estimate of -$0.28 by -$0.06.
Is Acumen Pharmaceuticals overvalued?
According to Wall Street analysts Acumen Pharmaceuticals’s price is currently Undervalued.
Does Acumen Pharmaceuticals pay dividends?
Acumen Pharmaceuticals does not currently pay dividends.
What is Acumen Pharmaceuticals’s EPS estimate?
Acumen Pharmaceuticals’s EPS estimate is -$0.36.
How many shares outstanding does Acumen Pharmaceuticals have?
Acumen Pharmaceuticals has 60,079,777 shares outstanding.
What happened to Acumen Pharmaceuticals’s price movement after its last earnings report?
Acumen Pharmaceuticals reported an EPS of -$0.34 in its last earnings report, missing expectations of -$0.28. Following the earnings report the stock price went up 8.203%.
Which hedge fund is a major shareholder of Acumen Pharmaceuticals?
Among the largest hedge funds holding Acumen Pharmaceuticals’s share is RA Capital Management. It holds Acumen Pharmaceuticals’s shares valued at 36M.
---
Acumen Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.00 (395.50% Upside)
$11.00 (395.50% Upside)
Blogger Sentiment
Bullish
ABOS Sentiment 100%
Sector Average 69%
Sector Average 69%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 5.3%
Last 30 Days ▼ 5.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-62.56%
12-Months-Change
Fundamentals
Return on Equity
-31.42%
Trailing 12-Months
Asset Growth
62.86%
Trailing 12-Months
Company Description
Acumen Pharmaceuticals
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what we believe to be a key underlying cause of Alzheimer's disease. The company's lead drug candidate, ACU193, is a subclass monoclonal antibody which selectively targets amyloid-beta oligomers.
---
ABOS Company Deck
---
ABOS Earnings Call
Q2 2024
0:00 / 0:00
---
ABOS Stock 12 Month Forecast
Average Price Target
$11.00
▲(395.50% Upside)
Technical Analysis
Best Analysts Covering ABOS
1 Year
1 Year Success Rate
3/11 ratings generated profit
1 Year Average Return
-33.22%
reiterated a buy rating 25 days ago
Copying Andrew Fein's trades and holding each position for 1 Year would result in 27.27% of your transactions generating a profit, with an average return of -33.22% per trade.
---